scholarly article | Q13442814 |
P356 | DOI | 10.4049/JIMMUNOL.175.6.4137 |
P698 | PubMed publication ID | 16148164 |
P50 | author | Helen Heslop | Q17386041 |
Karin Straathof | Q91736091 | ||
Catherine M Bollard | Q91774704 | ||
Cliona M Rooney | Q96221187 | ||
Ann M Leen | Q98164176 | ||
Elizabeth L Buza | Q101573240 | ||
M Helen Huls | Q109983498 | ||
P2093 | author name string | Graham Taylor | |
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | membrane protein | Q423042 |
P304 | page(s) | 4137-4147 | |
P577 | publication date | 2005-09-01 | |
P1433 | published in | Journal of Immunology | Q3521441 |
P1476 | title | Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma | |
P478 | volume | 175 |
Q47549907 | A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy |
Q35222179 | Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer |
Q57056125 | Adoptive cell therapy against EBV-related malignancies: a survey of clinical results |
Q37008216 | Adoptive cellular immunotherapy for childhood malignancies |
Q36513566 | Adoptive immunotherapy for Hodgkin's lymphoma |
Q34242449 | Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma |
Q40703339 | Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder. |
Q45398515 | CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. |
Q27014912 | Cellular immunotherapy for pediatric solid tumors |
Q37101134 | Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent |
Q36059593 | Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer |
Q45029775 | Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals |
Q37414729 | Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation |
Q37117769 | Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma |
Q37225034 | Emerging roles of small Epstein-Barr virus derived non-coding RNAs in epithelial malignancy |
Q33578792 | Engineered T cells for cancer treatment |
Q37129671 | Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients |
Q35238310 | Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector |
Q42632595 | Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs. |
Q90340855 | Generation of Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy |
Q38759383 | Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant |
Q33778708 | HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma |
Q34166497 | HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China |
Q35684896 | Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma. |
Q43238571 | Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. |
Q33303005 | Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy |
Q45077858 | Immune evasion strategies of the human gamma-herpesviruses: implications for viral tumorigenesis |
Q61797705 | Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation |
Q38803361 | Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma |
Q37268305 | Immunotherapy targeting EBV-expressing lymphoproliferative diseases |
Q33634455 | Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients |
Q59352682 | Novel ELISA for serodiagnosis of nasopharyngeal carcinoma based on a B cell epitope of Epstein-Barr virus latent membrane protein 2 |
Q28749468 | Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine |
Q45045503 | Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses |
Q33713932 | Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. |
Q47728296 | Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients |
Q59382383 | Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients |
Q40185976 | Rescue of the immunotherapeutic potential of a novel T cell epitope in the Epstein-Barr virus latent membrane protein 2. |
Q57176933 | Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target |
Q45368108 | Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination |
Q35068768 | Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins |
Q36821993 | T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI? |
Q47114749 | The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors |
Q34626576 | The molecular pathogenesis of Hodgkin lymphoma. |
Q37995110 | The pathological roles of BART miRNAs in nasopharyngeal carcinoma |
Q57056118 | Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes |
Q53547204 | Use of CD107-based cell sorting ex vivo to enrich subdominant CD8+ T cells in culture. |
Search more.